ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prevention"

  • Abstract Number: 1135 • ACR Convergence 2020

    Barriers to Influenza Vaccination in Patients at a Tertiary Care Rheumatology Clinic

    Audra Horomanski1, Gabriela Triant1, Kathleen Kolstad1, Melissa Dymock2 and Janice Lin1, 1Division of Immunology & Rheumatology, Stanford University School of Medicine, Palo Alto, CA, 2Department of Technology and Digital Solutions, Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Patients with rheumatologic conditions are at high risk of hospitalization, ICU admission, and death related to influenza infection due to their underlying diseases and…
  • Abstract Number: 1190 • ACR Convergence 2020

    Sex Differences in Cardiovascular Disease Prevention in Patients with Rheumatoid Arthritis: World-wide Data from the SURF-RA

    Elena Myasoedova1, Cynthia Crowson2, Joseph Sexton3, Silvia Rollefstad3 and Anne Grete Semb4, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, 3Diakonhjemmet Hospital, Oslo, Norway, 4Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway

    Background/Purpose: Rheumatoid arthritis (RA) is associated with 2-fold increase in risk of cardiovascular (CV) disease. Extensive evidence from the general population suggests that control of…
  • Abstract Number: 1742 • ACR Convergence 2020

    Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis

    Laurette van Boheemen1, Janne Bolt2, Marieke ter Wee3, Henriëtte de Jong2, Marleen van de Sande4 and Dirkjan van Schaardenburg5, 1Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, 2Amsterdam Rheumatology and immunology Center | Amsterdam UMC, Amsterdam, Netherlands, 3Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 4Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 5Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands

    Background/Purpose: Persons at risk of developing rheumatoid arthritis (RA) may benefit from lifestyle1 or pharmacological2 interventions aimed at primary prevention. Although less studied, the same…
  • Abstract Number: 1744 • ACR Convergence 2020

    The STAtins to Prevent Rheumatoid Arthritis (STAPRA) Trial: Clinical Results and Subsequent Qualitative Study, a Mixed Method Evaluation

    Laurette van Boheemen1, Marieke ter Wee2, Samina Turk3, Marian van Beers3, Wouter Bos3, Diane Marsman4, Ed Griep5, Mirian Starmans6, Calin Popa7, Alper van Sijl3, Bart Seppen3, Maarten Boers8, Mike Nurmohamed9 and Dirkjan van Schaardenburg8, 1Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, 2Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 3Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 4Sint Maartenskliniek, Nijmegen, Netherlands, 5Antonius Ziekenhuis, Sneek, Netherlands, 6Zuyderland MC, Heerlen, Netherlands, 7Radboudumc, Nijmegen, Netherlands, 8Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands, 9Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands

    Background/Purpose: Persons at high risk of developing rheumatoid arthritis (RA) may benefit from a low-risk pharmacological intervention aimed at primary prevention. Previous studies demonstrated disease-modifying…
  • Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting

    Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus

    Nancy Desai1, Hanni Menn-Josephy 1, Ramon Bonegio 1, Christina Lam 1, Anna Kancharla 1 and Michael York 1, 1Boston Medical Center, Boston

    Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
  • Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting

    Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center

    Ohoud AlAhmed1, Amanda Way 2, Shoghik akoghlanian 2, Fatima Barbar-Smiley 2, Stephanie Lemle 2, Darby MacDonald 2, Kelly Wise 2, Stacy Ardoin 2 and Vidya Sivaraman 3, 1Nationwide Children's Hospital, Columbu, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Nationwide Children's Hospital and The Ohio State University, Columbus, OH

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
  • Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting

    The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids

    Kengo Akashi1, Sadao Jinno 2, Akira Onishi 1, Mai Yamashita 3, Yoko Nose 4, Takaichi Okano 1, Yo Ueda 1, Sho Sendo 1, Jun Saegusa 1 and Akio Morinobu 1, 1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, 3Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, 4Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan

    Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
  • Abstract Number: 2268 • 2019 ACR/ARP Annual Meeting

    Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation

    Chelsie Fleischer1, Marie Feser 2, Elizabeth Bemis 3, Christopher Striebich 4, LauraKay Moss 4, Vasilisa Kormendi 5, Sharon White 5, V. Michael Holers 6, Mark Harrison 7 and Kevin Deane 2, 1University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, 4University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, 5University of Colorado Denver, School of Medicine, Aurora, CO USA, Aurora, CO, 6University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 7The University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, Vancouver, BC, Canada

    Background/Purpose: In rheumatoid arthritis (RA) development, autoantibodies to citrullinated protein antigens (ACPA) are elevated in the blood before clinically-apparent synovitis develops. These findings underpin the…
  • Abstract Number: 295 • 2018 ACR/ARHP Annual Meeting

    Implementing a Staff Tobacco Cessation Protocol Increases Quit Line Referrals in a Community Rheumatology Practice

    Ann M. Chodara1, Edmond Ramly2,3, Douglas White4, Heather Johnson5, Andrea Gilmore-Bykovskyi6 and Christie M. Bartels7, 1Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 2Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, 3Department of Family Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4Gundersen Lutheran - Onalaska Clinic, Onalaska, WI, 5Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, 6University of Wisconsin School of Nursing, Madison, WI, 7Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Smoking remains the leading preventable cause of US mortality and predicts higher incidence, greater severity, and reduced treatment response in many rheumatologic conditions. Despite…
  • Abstract Number: 344 • 2018 ACR/ARHP Annual Meeting

    Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project

    Melissa Swee1, Jaime Wilson2 and Bharat Kumar3, 1Transplant Nephrology, University of Iowa, Iowa City, IA, 2Iowa City Veterans Affairs Medical Center, Iowa City, IA, 3Internal Medicine-Division of Immunology, University of Iowa, Iowa City, IA

    Background/Purpose: Pneumonia is a leading cause of morbidity and mortality in the United States among immunocompromised individuals with rheumatologic diseases. Despite the publication of Advisory…
  • Abstract Number: 1235 • 2018 ACR/ARHP Annual Meeting

    Isoniazid Monotherapy As a Prophylaxis for Tuberculosis in Patients with Rheumatic Diseases Exposed to Prolonged, High-Dose Glucocorticoids

    Jun Won Park1, Jeffrey R. Curtis2, Hajeong Lee3, Yeong Wook Song4 and Eun Bong Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), 4Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

    Background/Purpose: Although use of glucocorticoid increases the risk of tuberculosis (TB) disease, there has been few studies investigating its incidence and risk/benefit assessment of the…
  • Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting

    Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting

    Linh Truong1, Nicole Ridolfi1 and Maida Wong2,3, 1Internal Medicine, University of California, Irvine, Orange, CA, 2Department of Medicine, University of California, Irvine, orange, CA, 3Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA

    Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
  • Abstract Number: 1642 • 2018 ACR/ARHP Annual Meeting

    Systematic Screening of Comorbidities Improves Vaccination Rates, Skin Cancer Screening and Vitamin D Supplementation in Patients with Axial Spondyloarthritis: Results of a Prospective, Controlled ,One Year Randomised Trial

    Anna Molto1, Adrien Etcheto2, Serge Poiraudeau3, Laure Gossec4, Pascal Claudepierre5, Martin Soubrier6, Françoise Fayet7, Daniel Wendling8, Philippe Gaudin9, Emmanuelle Dernis10, Sandrine Guis11, Sophie Pouplin12, Adeline Ruyssen-Witrand13 and Maxime Dougados14, 1Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, 2Department of Rheumatology, Paris Descartes University, Hôpital Cochin, Paris, France, 3Univ. Paris Descartes, PRES Sorbonne Paris, INSERM UMR-S 1153 et Institut fédératif de recherche sur le handicap, Paris, France, Paris, France, 4Rhumatologie, Médecine Sorbonne Université, Pitié-Salpétrière Hospital, Paris, France, 5Hôpital Henri Mondor, Créteil, France, 6Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 7CHU Gabriel Montpied, Clermont Ferrand, France, 8Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, 9Grenoble University Hospital, France, Grenoble, France, 10Service de Rhumatologie, CH du Mans, Le Mans, France, 11Rheumatology Department, CHU, Marseile, France, 12Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 13Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, 14Paris Descartes University, Hôpital Cochin, Paris, France

    Background/Purpose: Specific recommendations for the detection/prevention of comorbidities have been proposed for patients with SpA. However, we know that often a gap exists between recommendation…
  • Abstract Number: 1909 • 2018 ACR/ARHP Annual Meeting

    Impact and Timing of Smoking Cessation on Reducing Risk for Seropositive Rheumatoid Arthritis Among Women

    Xinyi Liu1, Cianna Leatherwood1, Sara K. Tedeschi1, Medha Barbhaiya2, Cameron Speyer1, Bing Lu3, Karen Costenbader1, Elizabeth Karlson1 and Jeffrey A. Sparks1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Division of Rheumatology, Immunology and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Compared to never smoking, past and current smoking are both associated with increased risk of seropositive rheumatoid arthritis (RA). Thus, smoking cessation may delay…
  • Abstract Number: 841 • 2017 ACR/ARHP Annual Meeting

    Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial

    Masayoshi Harigai1,2, Masako Utsunomiya2,3,4, Hiroaki Dobashi5, Toshio Odani6,7, Kazuyoshi Saito8,9, Naoto Yokogawa10, Kenji Nagasaka11,12, Kenchi Takenaka3,11, Makoto Soejima11,13, Takahiko Sugihara14, Hiroyuki Hagiyama15, Shinya Hirata16, Kazuo Matsui17,18, Yoshinori Nonomura19, Masahiro Kondo20, Fumihito Suzuki13,21, Makoto Tomita22, Mari Kihara23, Waka Yokoyama3, Fumio Hirano24, Hayato Yamazaki3, Ryoko Sakai2,25, Toshihiro Nanki2,26, Ryuji Koike2,3, Hitoshi Kohsaka3 and Nobuyuki Miyasaka3, 1Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 4Department of Rheumatology, Musashino Red Cross Hospital, Tokyo, Japan, 5Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan, 6Third Department of Internal Medicine, Obihiro-Kosei General Hospital, Hokkaido, Japan, 7Molecular Physiology and Therapeutics Branch/Adeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research (NIDCR)/ National Institutes of Health (NIH), Bethesda, MD, 8Tobata General Hospital, Fukuoka, Japan, 9The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 10Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 11Department of Rheumatology, Ome Municipal General Hospital, Tokyo, Japan, 12Department of Pharmacovigilance, Graduate School of Medical and Dental Sciences,, Tokyo Medical and Dental University, Tokyo, Japan, 13Department of Rheumatology, Soka Municipal Hospital, Saitama, Japan, 14Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 15Department of Rheumatology, Yokohama City Minato Red Cross Hospital, Kanagawa, Japan, 16Department of Hematology, Rheumatology, and Infectious Disease, Kumamoto University, Kumamoto, Japan, 17Department of Rheumatology, Kameda Medical Center, Chiba, Japan, 18Department of Internal Medicine, Takikawa Municipal Hospital, Hokkaido, Japan, 19Department of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan, 20Department of Rheumatology, Faculty of Medicine, Shimane University, Shimane, Japan, 21Department of Rheumatology, JA Toride Medical Center, Ibaraki, Japan, 22Clinical Research Center, Tokyo Medical and Dental University, Tokyo, Japan, 23Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 24Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 25Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 26Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan

    Background/Purpose: Sulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PCP), but is sometimes discontinued due to adverse events (AEs). We have…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology